国际皮肤性病学杂志    2003 29 (2): 74-77   ISSN: 2096-5540  CN: 32-1880/R   咪喹莫特的实验室与临床研究进展 吴剑波, 郑家润 中国医学科学院、中国协和医科大学皮肤病研究所, 南京210042 收稿日期 2002-09-18  修回日期 null  网络版发布日期 null 参考文献  [1] Sauder DN. Immunomodulatory and pharmacologic properties of imi quimod. J Am Acad Dermatol, 2000, 43(1 Pt 2):S6-11. [2] Buates S, Matlashewski G. Identification of genes induced by a macrophage activator, S-28463, using gene expression array analysis. Antimicrob Agents Chemother, 2001,45 (4):1137-1142. [3] Bums RP Jr, Ferbel B, Tomai M,et al. The imidazoquinolines, imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clin Immunol, 2000, 94(1):13-23. [4] Wagner TL, Ahonen CL, Couture AM, et al. Modulation of TH1 and TH2 cytokine production with the immune response modifiers, R 848 and imiquimod. Cell Immunol, 1999, 191 (1):10-19. [5] Bishop GA, Ramirez LM, Baccam M, et al. The immune response modifier resiquimod mimics CD40-induced B cell activation. Cell Immunol, 2001, 208(1):9-17. [6] Hemmi H, Kaisho T, Takeuchi O,et al. Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway. Nat Immunol, 2002, 3 (2):196-200. [7] Soria I, Myhre P, Horton V, et al. Effect of food on the pharmacoki netics and bioavailability of oral imiquimod relative to a subcutaneous dose. Int J Clin Pharmacol Ther, 2000, 38(10):476-481. [8] Owens ML, Bridson WE, Smith SL, et al. Percutaneous penetration of Aldara cream, 5% during the topical treatment of genital and peri anal warts. Prim. Care Update Ob Gyns, 1998, 5(4):151. [9] Beutner KR, Tyring SK, Trofatter KF Jr, et al. Imiquimod, a patient applied immune-response modifier for treatment of external genital warts. Antimicrob Agents Chemother, 1998, 42(4):789-794. [10] Goldstein D, Hertzog P, Tomkinson E, et al. Administration of imi quimod, an interferon inducer, in asymptomatic human immunodeficiency virus-infected persons to determine safety and biologic response modification. J Infect Dis, 1998, 178 (3):858-861. [11] Savage P, Horton V, Moore J, et al. A phase I clinical trial of imi quimod, an oral interferon inducer, administered daily. Br J Cancer, 1996, 74(9):1482-1486. [12] Beutner KR, Spruance SL, Hougham AJ, et al. Treatment of genital warts with an immune-response modifier (imiquimod). J Am Acad Dermatol, 1998, 38(2 Pt 1):230-239. [13] Garland SM, Sellors JW, Wikstrom A, et al. Imiquimod 5% cream is a safe and effective self-applied treatment for anogenital warts-results of an open-label, multicentre Phase ⅢB trial. Int J STD AIDS, 2001, 12(11):722-729. [14] Moore RA, Edwards JE, Hopwood J,et al. Imiquimod for the treat ment of genital warts:a quantitative systematic review. BMC Infect Dis, 2001,1(1):3. [15] Arany I, Tyring SK, Stanley MA, et al. Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Res, 1999, 43 (1):55-63. [16] Arrese J, Paquet P, Claessens N, et al. Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. J Cutan Pathol, 2001,28(3):131-134. [17] Liota E, Smith KJ, Buckley R, et al. Imiquimod therapy for mollus cum contagiosum. J Cutan Med Surg, 2000, 4(2):76-82. [18] Schacker TW, Conant M, Thoming C, et al. Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis:a phase Ⅱ, randomized, double-blind, placebo-controlled study. Antimicrob Agents Chemother, 2002, 46(10):3243-3248. [19] Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with imiquimod cream 5%:a report of six cases. Br J Dermatol, 2001, 144(5):1050-1053. [20] Todd RW, Etherington IJ, Luesley DM. The effects of 5% imiquimod cream on high-grade vulval intraepithelial neoplasia. Gynecol Oncol, 2002, 85(1):67-70. [21] Smith KJ, Germain M, Skelton H. Bowen's disease (squamous cell carcinoma in situ) in immunosuppressed patients treated with imi quimod 5% cream and a cox inhibitor, sulindac:potential applications for this combination of immunotherapy. Dermatol Surg, 2001, 27(2):143-146. [22] Mackenzie-Wood A, Kossard S, de Launey J,et al. Imiquimod 5% cream in the treatment of Bowen's disease. J Am Acad Dermatol, 2001,44(3):462-470. [23] Marks R, Gebauer K, Shumack S, et al. Imiquimod 5% cream in the treatment of superficial basal cell carcinoma:results of a multicenter 6-week dose-response trial. J Am Acad Dermatol, 2001,44(5):807-813. [24] Geisse JK, Rich P, Pandya A, et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma:a double-blind, randomized, vehicle-controlled study. J Am Acad Dermatol, 2002, 47 (3):390-398. [25] Bong AB, Bonnekoh B, Franke I, et al. Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology, 2002, 205 (2):135-138. 通讯作者: